MyoKardia Gets $38M For Heart Disease Treatment
San Francisco-based Myokardia, a newly formed developer of small molecule therapeutics, said today that it is targeting genetic heart disease with $38M in funding. The Series A funding came from Third Rock Ventures. MyoKardia is developing treatments for hypertrophic and dilated cardiomyopathy.
posted on Thursday, September 20, 2012 (Link to more information)
Related companies:
MyoKardia Inc
Related stories:
> MyoKardia Finds $46M For Treating Genetic Heart Disease
> EBR Systems Raises $50M For Wireless Heart Failure Treatment System
> EBR Systems Gets $35M In Third Round
> Portaero Quietly Gets Funding For COPD Treatment
> CardioKinetix Scores $48M For Heart Failure Treatment
silicontap.com Home